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Abstract
Introduction: Bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis that
has been used to treat urothelial carcinoma since 1976, and has been reported to eradicate disease in
more than 70% of patients with in situ and stage I disease. To the best of our knowledge, we report
the first case of disseminated bacillus Calmette-Guerin infection causing multiple abscesses affecting
the pancreatic head and right psoas muscle, diagnosed 5 years after intravesical treatment with
bacillus Calmette-Guerin therapy for bladder cancer.
Case presentation: An 83-year-old Caucasian man was hospitalized with a 2-month history of back
pain, anorexia, generalized weakness and a 47-pound weight loss. He had previously undergone two
transurethral resections for high-grade transitional cell carcinoma of the bladder and had received
12 intravesical bacillus Calmette-Guerin instillations without any complications. He complained of
abdominal pain in his right flank. A computed tomography scan of the abdomen showed multiple
abscesses affecting the pancreatic head and right psoas muscle. Growth of Mycobacterium bovis was
determined in cultures of the purulent material obtained by surgical drainage of the abscesses.
Conclusions: This case illustrates the fact that although intravesical administration of bacillus
Calmette-Guerin is generally considered to be safe, it is not exempt from complications and these
could appear immediately after treatment or as a delayed complication many years later.
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Bacillus Calmette-Guerin (BCG) is a live attenuated strain
of Mycobacerium bovis that has been used to treat urothelial
carcinoma since 1976 and has been reported to eradicate
diseaseinmorethan70%ofpatientswithinsituandstageI
disease [1]. Although intravesical therapy with BCG is
generally considered safe, serious complications including
hematuria, granulomatous pneumonitis, suppurative lym-
phadenitis, distant intramuscular and bone abscesses,
hepatitis, and life-threatening BCG sepsis have been
documented [2]. The reported incidence of complications
other than minor ones is under 5% [3]. To the best of our
knowledge, we report the first case of disseminated BCG
infection causing multiple abscesses affecting the pancrea-
tic head and right psoas muscle diagnosed 5 years after
intravesicaltreatmentwithBCGtherapyforbladdercancer.
Case presentation
An 83-year-old Caucasian man was hospitalized with a
2-month history of back pain, anorexia, generalized
weakness and a 47-pound weight loss. The patient had
previously undergone two transurethral resections for
high-grade urothelial carcinoma of the bladder, receiving
12 intravesical BCG instillations without any complica-
tions. Due to tumor progression, he had undergone a
radical cystoprostatectomy 5 years earlier and had also had
an endovascular stent-graft repair of an infrarenal abdom-
inal aortic aneurysm. The patient complained of abdom-
inal pain in his right flank.
A physical examination revealed general poor health but
pulmonary and cardiac examinations were unremarkable
and the patient was afebrile. Laboratory investigations were
normal with the exception of anemia, a mild renal
insufficiency, a left shift of the leucocyte differential and
elevated liver enzymes. A computed tomography (CT)
scan of the abdomen showed multiple abscesses affecting
the pancreatic head (Figure 1) and right psoas muscle
(Figure 2). Surgical exploration and drainage were per-
formed and cultures of the purulent material were positive
forM.bovis.Urineandbloodcultureswerenegativeforacid-
fast bacilli stains. Antitubercular treatment with isoniazid
300 mg/day, rifampicin 600 mg/day and ethambutol
1200 mg/day was administered for 2 months maintaining
isoniazidandrifampicinforafurther4months.Clinicaland
laboratory findings improved and after 3 weeks, laboratory
testswerenormal.Afollow-upabdominalCTscanobtained
8 weeks after starting the treatment showed a marked
improvement in the extension of the psoas abscess and the
number of masses present. The patient remains clinically
well after 6 months of the antituberculous therapy.
Discussion
Intravesical administration of BCG has proved to be an
effective form of treatment for some stages of bladder
cancer [4]. There are specific risks usually because the
virulence is attenuated but the bacillus is still viable and
possesses allergic properties. Infrequent, serious complica-
tions of this treatment have become apparent as its use has
become more widespread. Local complications of BCG
therapy for bladder cancer include cystitis, prostatitis,
epididymo-orchitis, granulomatous lymphadenitis, uret-
eral obstruction [5], and more rarely, prostatic abscess [6]
and infection of the glans penis [7]. Systemic side effects
Figure 1. Computed tomography scan showing 43 mm
abscess affecting the pancreatic head.
Figure 2. Computed tomography scan showing right psoas
abscess.
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pneumonitis, hepatitis, rash, arthralgia and arthritis, renal
abscess, cytopenia and sepsis. The frequency of these
adverse effects was reported by Lammet al. [2] in a study of
more than 1200 patients who received this type of
immunotherapy. The results revealed only a 2.9%
incidence of high fever (>39°C), 1.0% major hematuria,
0.9% granulomatous prostatitis, 0.7% granulomatous
pneumonitis and/or hepatitis, 0.5% arthritis or arthralgia,
0.4% epididymo-orchitis, 0.4% life-threatening BCG
sepsis, 0.3% urethral obstruction, 0.2% bladder contrac-
ture, 0.1% renal abscess and 0.1% cytopenia.
There are also rare cases described in the literature of some
other major complications such as mycotic abdominal
aortic aneurysm [8], infection of an implantable defibril-
lator [9], vertebral osteomyelitis [10] and bilateral
panuveitis [11]. No infection of the pancreatic head was
found in a review of the literature on PubMed.
The mechanism by which BCG exerts its antitumor activity
is unknown, but it has been suggested that a non-specific
immune response to BCG might also destroy tumor cells
[2]. Another suggested mechanism is that the severe
inflammation caused by BCG leads to local ischemia,
thereby killing tumor cells [3]. Hematogenous spread of
BCG and immunoallergic reactions are the two main
mechanisms behind the development of systemic com-
plications [2]. Hematogenous spread through an inflamed
and/or disrupted urothelium is most frequently caused by
traumatic catheterization, bladder perforation, or by
extensive tumor resection [3]. In acutely ill patients, triple
antituberculous therapy is recommended for 6 months
[2]. The use of corticosteroids has risks but the demon-
strated absence of organisms in many patients with diffuse
granulomas suggests that these complications may be the
result of type IV hypersensitivity reactions [12-14].
Conclusions
Although major complications from intravesical BCG
treatment are rare, it may result in prolonged fever,
pneumonitis, arthritis, vertebral osteomyelitis, hepatitis
or life-threatening sepsis. Symptomatology is probably
produced jointly by dissemination of M. bovis to the
reticuloendothelial system and a hypersensitivity
response. Antituberculosis agents other than pyrazina-
mide in combination with corticosteroids are the treat-
ment of choice for disseminated BCG infection. A CT scan
is the diagnostic tool of choice in cases of abscesses, with
rapid evaluation followed by adequate drainage and
antituberculosis agents as the key to the survival of the
patient. Our patient improved clinically and although he
had recovered fully after 2 months of treatment, he
completed the scheduled 9-month treatment. This case
reminds us that although intravesical administration of
BCG has proved to be a generally safe treatment, it is not
exempt from complications and these could appear
immediately after treatment or as a delayed complication
many years later.
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